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Aims Contemporary data regarding atrial fibrillation (AF) management and current use of oral anticoagulants (OACs) for
stroke prevention are needed.
...................................................................................................................................................................................................
Methods
and results
The EURObservational Research Programme on AF (EORP-AF) Long-Term General Registry analysed consecutive
AF patients presenting to cardiologists in 250 centres from 27 European countries. From 2013 to 2016, 11 096 pa-
tients were enrolled (40.7% female; mean age 69 ± 11 years). At discharge, OACs were used in 9379 patients
(84.9%), with non-vitamin K antagonists (NOACs) accounting for 40.9% of OACs. Antiplatelet therapy alone was
used by 20% of patients, while no antithrombotic treatment was prescribed in 6.4%. On multivariable analysis, age,
hypertension, previous ischaemic stroke, symptomatic AF and planned cardioversion or ablation were independent
predictors of OAC use, whereas lone AF, previous haemorrhagic events, chronic kidney disease and admission for
acute coronary syndrome (ACS) or non-cardiovascular causes independently predicted OAC non-use. Regarding
the OAC type, coronary artery disease, history of heart failure, or valvular heart disease, planned cardioversion
and non-AF reasons for admission independently predicted the use of vitamin K antagonists (VKAs). Wide variabil-
ity among the European regions was observed in the use of NOACs, independently from other clinical factors.
...................................................................................................................................................................................................
Conclusion The EORP-AF Long-Term General Registry provides a full picture of contemporary use of OAC in European AF
patients. The overall rate of OACs use was generally high (84.9%), and a series of factors were associated with the
prescription of OAC. A significant geographical heterogeneity in prescription of NOACs vs. VKAs was evident.
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Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia en-
countered in clinical practice and is particularly frequent in the eld-
erly.1,2 AF is associated with adverse outcomes and particularly with a
significantly increased risk of stroke, death, and heart failure.1 Oral anti-
coagulant (OAC) therapy significantly reduces the risk of AF-related
thromboembolic events and mortality and should be recommended in
every patient at risk.1 In recent years, the availability of non-vitamin K
antagonist oral anticoagulants (NOACs) as an alternative to vitamin K
antagonist (VKA) has offered new opportunities for stroke prevention
in AF patients, but there is still the need to assess the actual implemen-
tation of these evidence-based therapies in ‘real-world’ clinical practice.
The European Society of Cardiology (ESC)-sponsored EURObser-
vational Research Programme on AF (EORP-AF) General Long-
Term Registry aimed to evaluate contemporary management of AF
patients by European cardiologists and physicians, the current use of
VKA, NOACs and other treatments in AF, in relation to guideline
recommendations. The EORP-AF General Long-Term Registry fol-
lows the EORP-AF Pilot Registry, which provided initial information
on a smaller cohort from a limited number of countries in the early
period following the introduction of NOACs.3–5
The main aim of this article was to report the baseline clinical profile
of AF patients enrolled in EORP AF General Long-Term Registry.
Secondly, we focused on reporting specifically about OAC therapy use
and to explore the main clinical determinants of OAC prescription as
well as the factors influencing prescription of either VKA or NOACS.
Methods
Study cohort
The EORP-AF Long-Term General Registry is a prospective, observa-
tional, large-scale multicentre registry sponsored and conducted by the
ESC, enrolling AF patients in current cardiology practices in 250 centres
from 27 participating ESC countries. Patients were enrolled consecutively
when presenting with AF as primary or secondary diagnosis to inpatients
and outpatient cardiology services from October 2013 to September
2016. Main inclusion criteria were the following: (i) the qualifying AF
event had to be recorded by a 12-lead ECG, 24 h ECG Holter, or other
electrocardiographic documentation within 12 months before enrol-
ment; (ii) age should be 18 years and older; and (iii) written informed con-
sent form. Exclusion criteria were the following: (i) no objective proof of
AF; (ii) being previously enrolled in the EORP-AF Pilot Registry; or (iii)
being or planned to be enrolled in a pharmacological interventional clinical
trial. The study protocol was substantially similar to that of the EORP-AF
Pilot Registry reported elsewhere.3–5 An institutional review board for
every participating institution approved the study protocol. The study was
performed according to the European Union Note for Guidance on Good
Clinical Practice CPMP/ECH/135/95 and the Declaration of Helsinki.
All data about baseline clinical characteristics and previous clinical his-
tory (Table 1), as well as history of previous interventional procedures
(see Supplementary material online, Table S1), were collected by any
investigator/sub-investigator during the clinical interview and/or using
clinical notes and electronic clinical data archives, when available. Specific
characteristics about main reasons for admission/consultation and symp-
tomatic status (Table 2), as well as specific diagnostic procedures and
interventional procedures performed during the admission/consultation
(see Supplementary material online, Table S2), were collected at the mo-
ment of enrolment by any investigator and reported in specific study
notes. All data collected were then entered into an electronic case report
form. Data about the AF qualifying episode were compulsory, and all
other data have been provided when available.
Thromboembolic risk was defined according to CHA2DS2-VASc
[Congestive Heart Failure, Hypertension, Age >_75 years, Diabetes
Mellitus, Stroke/Transient Ischaemic Attack, Vascular Disease, Age 65-
74 years, Sex Category (Female)] score.6 Bleeding risk was assessed ac-
cording to HAS-BLED [Hypertension, Abnormal renal/liver function,
Stroke, Bleeding, Labile INR, Elderly (>65 years), Drug/Alcohol consump-
tion].7 Symptomatic status was defined according to (European Heart
Rhythm Association (EHRA) score.1
Participating countries were grouped in European regions as
follows: (i) Northern Europe—Denmark, Estonia, Latvia, Norway, UK;
(ii) Western Europe—Belgium, France, Germany, Netherlands,
Switzerland; (iii) Eastern Europe—Bulgaria, Czech Republic, Georgia,
Kazakhstan, Kyrgyzstan, Poland, Romania, Russia; and (iv) Southern
Europe—Albania, FYR Macedonia, Italy, Malta, Montenegro, Portugal,
Serbia, Spain, Turkey.
Statistical analysis
Continuous variables were reported as mean ± standard deviation or as
median and interquartile range (IQR). Among-group comparisons were
made using a non-parametric test (Kruskall–Wallis test). Categorical vari-
ables were reported as counts and percentages. Among-group compari-
sons were made using a v2 test or the Fisher’s exact test (if any expected
cell count was less than five). For qualitative variables, with more than two
possibilities, the Monte Carlo estimates of the exact P-values are used.
A stepwise multiple logistic regression analysis was used to determine
the clinical factors associated with OAC prescription, including in the
model all the candidate variables (variables with P< 0.10 in univariate).
A significance level of 0.05 is required to allow a variable into the model
(SLENTRY = 0.05) and a significance level of 0.05 is required for a variable
to stay in the model (SLSTAY = 0.05). No interaction was tested.
A Hosmer and Lemeshow goodness-of-fit test was used to verify that the
What’s new?
• In recent years, the management of atrial fibrillation (AF) has
progressively changed, for example, with the introduction of
non-vitamin K antagonist oral anticoagulants (NOACs) instead
of vitamin K antagonist (VKA).
• The EURObservational Research Programme on AF Long-
Term General Registry provides an overall comprehensive pic-
ture of AF management among European countries.
• Treatment with oral anticoagulant was high, mostly due to the
progressive uptake of NOACs, and can be associated with
various clinical features.
• Geographical variation was found in the prescription of
NOACs over VKA, with Northern and Western European
countries being those where NOACs were most prescribed.
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model was optimal. A similar approach was then used to establish the
clinical factors associated with either VKA or NOAC prescription.
A two-sided P-value <0.05 was considered statistically significant. All ana-
lyses were performed using SAS statistical software version 9.3 (SAS
Institute, Inc., Cary, NC, USA).
Results
From October 2013 to September 2016, 11 096 patients were en-
rolled in 250 centres from 27 participating ESC countries, 40.7% female;
median (IQR) age 71 (63–77) years. Overall, 5161 (68.5%) patients
were enrolled in a specialized centre, whereas 52.2% of patients were
enrolled in-hospital and 47.8% were enrolled as outpatients.
Hypertension was the most commonly reported co-morbidity
(62.1%), whereas 3058 patients had a concomitant diagnosis of cor-
onary artery disease, with most (44.0%) patients reporting a previous
myocardial infarction. A concomitant diagnosis of heart failure was
found in 4343 (39.5%) patients with 35.9% reporting New York
Heart Association (NYHA) Class III/IV. A previous thromboembolic
event (defined as previous stroke, TIA, or systemic embolism) was
recorded in 1274 (11.6%) patients. Among non-cardiac risk factors
or co-morbidities, chronic kidney disease was the most commonly
reported (12.5%). Overall, median (IQR) CHA2DS2-VASc was
3 (2–4), whereas median (IQR) HAS-BLED score was 1 (1–2).
AF was the main reason for admission in most of the patients
(7303, 65.8%). The most reported AF subtype was permanent AF
(33.5%), whereas 25.7% (2850) of patients reported a paroxysmal
AF. Baseline and patient characteristics at admission according to AF
subtypes are reported in Tables 1 and 2.
Baseline clinical characteristics and
previous clinical history
Compared to the other subtypes, permanent AF patients were older
[median (IQR) age 75 (67–80) years] than those with paroxysmal and
persistent AF [median (IQR) age 68 (60–75) years] (P< 0.0001).
Patients with paroxysmal AF were more likely to be female
(P< 0.0001). First detected AF patients were more likely to be
hospitalized than the other subtypes (P< 0.0001).
Both hypertension and coronary artery disease, as well as heart
failure, valvular disease and dilated cardiomyopathy, were more com-
monly reported in patients with permanent AF (all P< 0.0001).
Conversely, myocardial infarction was more likely have occurred in
patients with first detected AF (53.2%; P= 0.0007). Lone AF was
more prevalent in patients with first detected and paroxysmal AF
(11.9% and 11.7%, respectively; P< 0.0001).
Among concomitant risk factors, diabetes mellitus and absence of
regular exercise were more likely reported in patients with perman-
ent AF (29.1% and 51.0%, respectively; P< 0.0001), whereas lipid dis-
orders were more common in patients with paroxysmal AF (44.0%),
long-standing AF (43.0%), and permanent AF (43.2%) (P< 0.0001).
Active smoking was more prevalent in patients with first detected
AF. Patients with permanent AF had more prevalent non-cardiac co-
morbidities, such as chronic obstructive pulmonary disease (12.4%),
previous thromboembolic events (14.0%), previous stroke (8.7%),
previous haemorrhagic event (7.7%), peripheral vascular disease
(10.7%), and chronic kidney disease (17.9%) (all P< 0.0001).
Patient characteristics on admission/
consultation
AF was more commonly reported as the main reason for admission/
consultation in patients with persistent AF (83.9%), whereas heart
failure was the most common reason for admission with permanent
AF (19.7%) (P< 0.0001). Patients with permanent AF were more
likely to be asymptomatic (60.7%), whereas patients with first-
detected AF were more commonly symptomatic (67.3%)
(P< 0.0001). Among the asymptomatic patients, those with paroxys-
mal AF were more frequently symptomatic in the past (63.4%), com-
pared with other AF subtypes (P< 0.0001).
Previous interventions and procedures
during admission/consultation
The history of previous interventions is reported in Supplementary
material online, Table S1. Approximately a quarter of patients (2347
patients, 23.0%) underwent a pharmacological cardioversion proced-
ure in their recent clinical history, more commonly among inpatients
with paroxysmal AF (P< 0.0001). Electrical cardioversion was used in
19.2%, especially in those with persistent AF (P< 0.0001).
During the admission (or at the moment of consultation), the
most common diagnostic investigation procedure was transthoracic
echocardiography (86.1%), followed by Holter monitoring (29.0%),
coronary angiography (23.7%), and exercise testing (15.9%) (see
Supplementary material online, Table S2). Also, electrical cardiover-
sion was mostly used during admission (or planned during consult-
ation) in patients with persistent AF (45.2%, P< 0.0001).
Pharmacological cardioversion was mostly used (or planned) in pa-
tients with first-detected AF (17.5%) compared to those with parox-
ysmal AF (12.5%) (P< 0.0001).
Thromboembolic and bleeding risks
Thromboembolic and bleeding risks according to AF subtypes have
been reported in Table 3. Patients with permanent AF reported the
highest thromboembolic risk (CHA2DS2-VASc mean ± SD 3.77 ±
1.65) and bleeding risk (HAS-BLED mean ± SD 1.83 ± 1.05) com-
pared to patients with other AF subtypes (both P< 0.0001); also,
they reported the highest prevalence of most thromboembolic and
bleeding risk factors (see Supplementary material online, Table S3).
Antithrombotic treatments
As shown in Table 4, in most of the patients (9379, 84.9%), an OAC
drug was used, less likely prescribed in paroxysmal AF and
first-detected AF (P< 0.0001). Also, 2212 (20.0%) patients were pre-
scribed antiplatelet drugs, with the majority of them treated with
aspirin (1987 patients, 17.9%), mostly in patients with first-detected
AF and paroxysmal AF (both P< 0.0001).
Of those on OAC, half of the patients (50.2%) were treated with
a VKA, especially with permanent AF (P< 0.0001). Conversely, a
NOAC was used in 3835 (34.8%) patients, more likely in those diag-
nosed with with first-detected and persistent AF (P< 0.0001).
Among patients treated with OAC, a small proportion was treated
with concomitant antiplatelet drugs (1361 patients, 14.5%), more
likely in patients with first-detected AF (17.1%) (P< 0.0001).
Even in patients with low thromboembolic risk (CHA2DS2-VASc 0
in males), 447 (62.8%) patients were treated with OAC (Figure 1).
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Many of these (202 patients, 45.2%) underwent or were planned for
a cardioversion procedure (either pharmacological or electrical). In
patients with a higher CHA2DS2-VASc score, the use of OAC was
consistently high (around 80%). On the basis of the HAS-BLED score
(Figure 2), 1359 (77.3%) patients with HAS-BLED 0 were treated
with OAC as well as a similar, or even higher, proportion of patients
in the other score strata.
Overall, patients prescribed with OAC at discharge were older
(P< 0.0001) and had more prevalent cardiovascular risk factors (dia-
betes mellitus and lipid disorders), hypertension, and previous
thromboembolic events and stroke (see Supplementary material on
line, Table S4). Conversely, those patients not prescribed with OAC
were more likely to be affected by coronary artery disease, myocar-
dial infarction, peripheral vascular disease, and chronic kidney disease.
Comparing patients prescribed with VKA and NOACs (see
Supplementary material online, Table S5), patients prescribed with
NOACs were younger and had fewer risk factors and co-morbidities.
Patients with less established AF types (first-detected and paroxysmal
AF) were less likely prescribed with OAC (see Supplementary mater
ial online, Table S4), but when prescribed they were more likely pre-
scribed with NOACs (see Supplementary material online, Table S5).
Looking at regional distribution, OAC were more likely prescribed
in Western Europe (see Supplementary material online, Table S4),
whereas among OAC prescribed patients, NOACs were more likely
prescribed in both Northern and Western Europe (see
Supplementary material online, Table S5), in particular in Northern
Europe, as shown by the VKA/NOACs ratio, with Northern Europe
being the region that prevalently prescribe NOACs among the
others (Figure 3). Considering the year of enrolment, both OAC and
NOACs were prevalently more prescribed in the last 2 years of en-
rolment (both P< 0.0001).
After univariate analysis (see Supplementary material online, Table
S6), multivariable logistic analysis recognized several clinical factors as in-
dependent predictors of OAC use (Table 5, Panel A). Of these, progres-
sively increasing age (P< 0.0001), hypertension (P< 0.0001), previous
ischaemic stroke (P= 0.0024), and worsened symptomatic status
(P< 0.0001) were directly associated with the use of OAC; conversely,
a history of myocardial infarction (P= 0.0046), lone AF (P< 0.0001),
prior haemorrhagic events (P< 0.0001), and chronic kidney disease
(P= 0.0152) were inversely associated with OAC prescription.
Compared to first-detected AF, patients with persistent, long-standing
persistent and permanent AF were more likely associated with OAC
prescription (all P< 0.0001). Among reasons for admission/consultation,
those with acute coronary syndrome and hypertension were inversely
associated with the use of OACs (P< 0.0001 and P= 0.0031, respect-
ively). Also, compared to Eastern Europe, all the other European re-
gions were independently associated with OAC prescription (all
P< 0.0001), in particular those patients coming from Western Europe
were those more likely prescribed with OAC (Table 5, Panel A).
With regard to independent predictors of NOAC use vs. VKAs
(Table 5, Panel B), after selection of variables through a univariate ana-
lysis (see Supplementary material online, Table S7), multivariable ana-
lysis found that history of coronary artery disease (P< 0.0001), heart
failure (P= 0.0195), valvular heart disease (P< 0.0001), pulmonary ar-
terial hypertension (P= 0.0233), and pharmacological cardioversion
(P= 0.0001) were inversely associated with NOACs use. Compared
to first-diagnosed AF, all other AF subtypes were significantly in-
versely associated with the use of NOACs. Non-AF related causes of
admission were inversely associated with NOACs use. Compared to
those in Eastern Europe, patients prescribed with OAC in both
Northern and Western Europe were associated with NOACs pre-
scription (P= 0.0073 and P= 0.0018, respectively), while being in
Southern Europe was inversely associated with NOACs prescription
(P= 0.0005). Looking at the year of enrolment, being enrolled in the
EORP-AF Long-Term Registry more recently is directly associated
with NOACs prescription (Table 5, Panel B).
Discussion
The EORP-AF Long-Term General Registry provides an updated
‘snapshot’ of the management of AF in the cardiology setting, includ-
ing both inpatients and outpatients. The number of patients enrolled
(more than 11 000) recruited in 27 countries makes this independent
ESC-sponsored registry a relevant reference for depicting current
practice for AF patient management in Europe.
A few findings are confirmatory. AF patients are often elderly and
very frequently affected by several co-morbidities. Specifically, our
registry provides novel data on the current prescription of OACs
and on the prescription of NOACs vs. VKAs, with the advantage of
being an independent registry. At discharge, OACs were used in
84.9% of patients, with NOACs accounting for around 41% of all
OACs prescribed. As compared to EORP-AF Pilot data,3 this implies
an increase, even if just moderate, in the overall use of OACs in AF of
around 5% and should be viewed as a positive finding, able to coun-
teract the previously reported underuse of oral anticoagulation. As
....................................................................................................................................................................................................................
Table 3 Thromboembolic and bleeding risk scores
All First detected Paroxysmal Persistent Long-standing
persistent
Permanent Unknown P-value
CHA2DS2-VASc score
Median (IQR) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 3.0 (2.0–4.0) 3.0 (1.0–4.0) 3.0 (2.0–4.0) 4.0 (3.0–5.0) 3.0 (2.0–4.0) <0.0001
Mean ± SD 3.14 ± 1.77 2.84 ± 1.70 2.85 ± 1.79 2.73 ± 1.71 2.97 ± 1.71 3.77 ± 1.65 3.01 ± 1.62 <0.0001
HAS-BLED score
Median (IQR) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–2.0) 2.0 (1.0–2.0) <0.0001
Mean ± SD 1.56 ± 1.07 1.42 ± 1.06 1.44 ± 1.08 1.39 ± 1.04 1.42 ± 0.98 1.83 ± 1.05 1.59 ± 0.99 <0.0001
IQR, interquartile range; SD, standard deviation.
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Figure 1 Proportions of patients treated with antithrombotic drugs by CHA2DS2-VASc score. ATT, antithrombotic therapy; OAC, oral
anticoagulant.
Figure 2 Proportions of patients treated with antithrombotic drugs by HAS-BLED score. ATT, antithrombotic therapy; OAC, oral anticoagulant.
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previously reported,3 the rate of prescription according to
CHA2DS2-VASc and HAS-BLED indicates the tendency to underuse
OACs in patients who share both a high risk of bleeding and a high
risk of stroke. Conversely, the high proportion of patients treated
with OAC among those with low thromboembolic risk (CHA2DS2-
VASc 0 in males or 1 in females) still depict the need for better imple-
mentation of guideline recommendations, notwithstanding that some
patients were still undergoing diagnostic workup or were considered
for planned cardioversion or ablation procedures, leading to a tem-
porary increase in OAC prescription as per guidelines.1 Even the
lower likelihood of receiving OAC in patients with paroxysmal AF
still underlines the lack of adherence to guideline recommendations.
Our data show that the progressively increased use of OACs in AF
patients is largely due to the progressive increase in NOACs uptake,
as evident in several other large observational studies.8–10
In our EORP-AF General Long-Term Registry, we identified inde-
pendent predictors of OAC use, as well as of NOACs use, and this is
a novel finding of specific interest. The use of OACs was related to
most clinical characteristics and clinical conditions strongly associated
(or perceived as) with an increased thromboembolic risk (i.e. older
age, hypertension, previous thromboembolic events, and symptom-
atic AF), while all those conditions that usually imply an increased risk
of bleeding were found associated with OAC non-use (i.e. chronic
kidney disease and previous hemorrhagic events). In patients with
concomitant cardiovascular disease, OAC therapy was more likely
not to be used, despite the current guidelines recommendations.1
The EORP-AF General Long-Term General Registry clearly out-
lines a significant implementation of NOACs in thromboembolic
prophylaxis of AF, as compared to the picture reported by the
EORP-AF Pilot.3,11 Over a 4-year period, the rate of prescription of
NOACs increased from less than 10% of patients to around 35% of
patients, with a significant increase in the latter years independently
from all the other clinical factors, much likely reflecting the larger
availability of NOACs throughout the European countries. With re-
spect to independent predictors of NOACs, patients less clinically
complex were more likely to be treated with NOACs than com-
pared with VKA.
Comparing our results to data from the Outcomes Registry for
Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
study,12 different factors were associated with NOAC vs. VKA pre-
scription only partially overlapping with those showed by our results,
but a similar pattern was evident, with patients less affected with co-
morbidities more likely to be prescribed with NOACs. The finding
that NOAC prescription is inversely associated with both coronary
artery disease and pharmacological cardioversion procedure under-
lines how, despite some recent studies showing NOACs as safe alter-
natives in specific procedures such as coronary angiography13 and
direct cardioversion,14 there is still a need for more evidence and
physician awareness of safety of NOACs in such clinical scenarios. In
a recent analysis from the PINNACLE study, an industry-
independent US ‘real-life’ registry, predictors of both OAC and
NOACs use were analysed, and patients presenting with cardiovas-
cular and vascular disease were less likely treated both with OACs
and NOACs.10 Our results showed how even in European countries
a similar approach is still adopted.
The evidence presented significantly showed that clinical history of
heart failure is an important feature in determining the use of NOACs.
This evidence, together with those reported by ORBIT-AF II12 and
PINNACLE studies,10 suggest that despite the data coming from
randomized trials showing that NOACs are a valid alternative for AF
patients with heart failure,15 those patients are preferentially treated
with VKA.
Our data underline a large variability in the use of NOACs across
the European regions, clearly depicting a difference in acknowledge-
ment and application of ESC guidelines, which since 2012 substan-
tially recommend NOACs over VKAs. Despite the large effort to
improve the appropriate prescription of OACs and management of
AF patients, these differences appear to remain unchanged. Indeed,
even in a previous analysis from the EORP AF Pilot, patients coming
from Eastern and Southern Europe were less likely to be treated in
accordance with the guidelines recommendations,16 as highlighted
also by other data coming from Serbia17 and Italy.18 Notwithstanding,
given the heterogeneity of health care systems among European
countries, differences in affordability, prices, and compensations can-
not be excluded as partially influencing the prescription of NOACs.
The specific type of AF (first-detected, paroxysmal, persistent,
long-standing persistent, permanent) is associated with different pa-
tient profiles in terms of age, co-morbidities and associated diseases,
associated symptoms, regular exercise, reason for admission/consult-
ation, and risk factors for stroke and bleeding. Specifically, first-
detected AF is usually diagnosed in hospitalized patients and is less
frequently asymptomatic.19 In the EORP-AF Pilot Registry,3,20 we
found that patients with first-detected AF had characteristics similar
to persistent AF patients, but lower use of OAC. In the present ana-
lysis of the EORP-AF General Long-Term, we showed some im-
provement when compared wiyh EORP-AF Pilot.3,20
Strengths and limitations
The main limitation of our analysis is due to the observational nature
of the study. Moreover, the EORP-AF General Long-Term Registry is
based on cardiologists’ practice, so our data would be considered
carefully when extended to general practice. Also, since the EORP-
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Figure 3 Oral anticoagulant treatment distribution and VKA/
NOAC ratio at discharge by region NOAC, non-vitamin K
antagonist oral anticoagulant; OAC, VKA, vitamin K antagonist.
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AF Long-Term Registry followed the Pilot phase and all the enrolling
centres were also associated with ESC activities, we could hypothe-
size some selection bias that led to an overestimation of the overall
OAC uptake. A residual selection bias could have been also due to
the lack of full monitoring and audit visits that could not certify that
enrolment was actually consecutive. Furthermore, several clinical fac-
tors could have been either under- or overestimated. Nevertheless,
our data provide a comprehensive picture of current European AF
patients and cardiologists practice that will provide useful and reliable
insights in real-world clinical practice.
Conclusions
The EORP-AF Long-Term General Registry provides a full picture
of contemporary use of OACs in AF patients. The overall rate of
OAC use was generally high (84.9%), with several clinical factors
identified as independently associated with the prescription of
OACs and preferential use of NOACs over VKAs. A relevant geo-
graphical variability in the prescription of NOACs over VKAs was
also highlighted.
Supplementary material
Supplementary material is available at Europace online.
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Table 5 Multivariable analysis for Independent pre-
dictors of anticoagulant treatments
Odds
ratio
95% CI PWald
A. Independent predictors of OAC usea
Age 1.018 1.011–1.024 <0.0001
Hypertension 1.362 1.175–1.579 <0.0001
Myocardial infarction 0.747 0.611–0.914 0.0046
Angina 0.508 0.414–0.624 <0.0001
Lone AF 0.320 0.258–0.397 <0.0001
Hyperthyroidism 1.522 1.072–2.191 0.0239
Lipid disorder 1.243 1.083–1.427 0.0020
Previous ischaemic stroke 1.634 1.190–2.243 0.0024
Haemorrhagic events 0.424 0.331–0.543 <0.0001
Malignancy 0.722 0.572–0.912 0.0063
Chronic kidney disease 0.779 0.636–0.953 0.0152
Pharmacological cardioversion for AF 0.814 0.692–0.957 0.0126
Electrical cardioversion for AF 1.819 1.462–2.264 <0.0001
Catheter ablation for AF 1.641 1.141–2.264 0.0075
AF type
First-detected (reference)
Paroxysmal 0.921 0.763–1.11 0.3890
Persistent 2.209 1.749–2.788 <0.0001
Long-standing persistent 2.601 1.717–3.940 <0.0001
Permanent 2.214 1.798–2.726 <0.0001
Main reason for admission/consultation
AF (reference)
Acute coronary syndrome 0.481 0.357–0648 <0.0001
Heart failure 1.031 0.797–1.334 0.8145
Hypertension 0.527 0.345–0.806 0.0031
Other cardiovascular 0.810 0.628–1.046 0.1062
Other coronary artery disease 0.807 0.561–1.159 0.2456
Other non-cardiovascular 0.592 0.436–0.804 0.0008
Valvular heart disease 0.802 0.543–1.184 0.2669
EHRA II–IV 1.439 1.259–1.644 <0.0001
Region
Eastern Europe (reference)
Northern Europe 1.686 1.330–2.137 <0.0001
Southern Europe 1.443 1.212–1.718 <0.0001
Western Europe 2.840 2.305–3.499 <0.0001
B. Independent predictors of NOACs vs. VKA useb
Coronary artery disease 0.761 0.674–0.860 <0.0001
Heart failure 0.869 0.773–0.978 0.0195
Valvular heart disease 0.757 0.678–0.831 <0.0001
Pulmonary arterial hypertension 0.769 0.612–0.965 0.0233
Pharmacological cardioversion for AF 0.781 0.689–0.885 0.0001
AF type
First detected (reference)
Paroxysmal 0.755 0.642–0.887 0.0006
Persistent 0.769 0.654–0.905 0.0015
Long-standing persistent 0.612 0.476–0.788 0.0001
Permanent 0.343 0.294–0.402 <0.0001
Main reason for admission/consultation
AF (reference)
Acute coronary syndrome 0.613 0.441–0.852 0.0036
Heart failure 0.718 0.583–0.883 0.0017
Hypertension 0.777 0.545–1.107 0.1620
Other cardiovascular 0.496 0.406–0.607 <0.0001
Other coronary artery disease 0.734 0.529–1.017 0.0628
Other non-cardiovascular 0.573 0.455–0.721 <0.0001
Valvular heart disease 0.147 0.087–0.247 <0.0001
Region
Eastern Europe (reference)
Northern Europe 1.335 1.081–1.649 0.0073
Southern Europe 0.751 0.639–0.884 0.0005
Western Europe 1.313 1.107–1.559 0.0018
Continued
.................................................................................................
Table 5 Continued
Odds
ratio
95% CI PWald
Year of enrolment
2013 (reference)
2014 1.242 0.684–2.257 0.4768
2015 2.399 1.322–4.351 0.0040
2016 3.026 1.668–5.491 0.0003
AF, atrial fibrillation; CI, confidence interval; NOACs, non-vitamin K antagonist
oral anticoagulants; OAC, oral anticoagulant; VKA, vitamin K antagonist.
aHosmer and Lemeshow goodness-of-fit test: P= 0.0721, percent concordant =
74.9%.
bHosmer and Lemeshow goodness-of-fit test: P= 0.1337, percent concordant =
72.4%.
Page 10 of 11 G. Boriani et al.
Downloaded from https://academic.oup.com/europace/article-abstract/doi/10.1093/europace/eux301/4158403/Contemporary-stroke-prevention-strategies-in-11
by Sapienza Università di Roma user
on 14 September 2017
M.P. received a small consulting fee from Boehringer Ingelheim, outside
the submitted work; L.F. reports personal fees from Bayer, Boehringer
Ingelheim, BMS Pfizer, Medtronic, Novartis, outside the submitted
work; F.M. reports personal fees from Boehringer Ingelheim, Bayer,
and Pfizer-BMS, outside the submitted work; M.N. reports grants from
AFNET Germany, during the conduct of the study, lecture fees from
Boehringer Ingelheim, Bristol-Myers Squibb Germany, Pfizer Germany,
and Daichii-Sankyo Germany, outside the submitted work; T.P. reports
personal fees from Pfizer and Bayer, during the conduct of the study;
L.T. reports personal fees from Servier and CVIE Therapeutics, outside
the submitted work; A.P.M. has received grants and non-financial sup-
port as a Steering Committee member from Novartis, Cardiorentis,
Abbott Vascular and Bayer, also grants and non-financial support as a
DSMB Committee member from Servier, personal fees from
Fresenius, outside the submitted work; G.Y.H.L. has served as consult-
ant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer
Ingelheim, Microlife, and Daiichi-Sankyo, is speaker for Bayer, BMS/
Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche, and Daiichi-
Sankyo,and received no fees personally, outside the submitted work.
All other authors have no interest to disclose.
Funding
Since the start of EORP, the following companies have supported the
programme: Abbott Vascular Int. (2011-2014), Amgen Cardiovascular
(2009-2018), AstraZeneca (2014-2017), Bayer AG (2009-2018),
Boehringer Ingelheim (2009-2019), Boston Scientific (2009-2012), The
Bristol Myers Squibb and Pfizer Alliance (2011-2016), The Alliance Daiichi
Sankyo Europe GmbH and Eli Lilly and Company (2011-2017), Edwards
(2016-2019), Gedeon Richter Plc. (2014-2017), Menarini Int. Op. (2009-
2012), MSD-Merck & Co. (2011-2014), Novartis Pharma AG (2014-
2017), ResMed (2014-2016), Sanofi (2009-2011), and SERVIER (2009-
2018).The Atrial Fibrillation NETwork (AFNET), conducting the registry
in Germany, received support from The Bristol Myers Squibb/Pfizer
Alliance (2014-2018) and the German Centre for Cardiovascular
Research (DZHK).
References
1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC
Guidelines for the management of atrial fibrillation developed in collaboration
with EACTS. Europace 2016;18:1609–78.
2. Boriani G, Diemberger I, Martignani C, Biffi M, Branzi A. The epidemiological bur-
den of atrial fibrillation: a challenge for clinicians and health care systems. Eur
Heart J 2006;27:893–4.
3. Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH et al. A
prospective survey in European Society of Cardiology member countries of
atrial fibrillation management: baseline results of EURObservational Research
Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace
2014; 16:308–19.
4. Lip GYH, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L
et al. Prognosis and treatment of atrial fibrillation patients by European
cardiologists: one year follow-up of the EURObservational Research
Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot regis-
try). Eur Heart J 2014;35:3365–76.
5. Proietti M, Laroche C, Opolski G, Maggioni AP, Boriani G, Lip GYH et al. ‘Real-
world’ atrial fibrillation management in Europe: observations from the 2-year
follow-up of the EURObservational Research Programme-Atrial Fibrillation
General Registry Pilot Phase. Europace 2017;19:722–33.
6. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk
stratification for predicting stroke and thromboembolism in atrial fibrillation
using a novel risk factor-based approach: the euro heart survey on atrial fibrilla-
tion. Chest 2010;137:263–72.
7. Pisters R, Lane DA, Nieuwlaat R, Vos CB. D, Crijns HJGM, Lip GYH. A novel
user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in pa-
tients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093–100.
8. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand J-P, Berge E et al. Evolving
antithrombotic treatment patterns for patients with newly diagnosed atrial fibril-
lation. Heart 2017;103:307–14.
9. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener H-C, Dubner SJ et al.
The changing landscape for stroke prevention in AF: findings from the GLORIA-
AF Registry Phase 2. J Am Coll Cardiol 2017;69:777–85.
10. Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL et al. Influence of
direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation.
J Am Coll Cardiol 2017;69:2475–84.
11. Lip GYH, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al. ‘Real-
World’ antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey.
Am J Med 2014;127:519–29.e1.
12. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ et al.
Factors associated with non-vitamin K antagonist oral anticoagulants for stroke
prevention in patients with new-onset atrial fibrillation: Results from the
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II
(ORBIT-AF II). Am Heart J 2017;189:40–7.
13. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P et al.
Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J
Med 2016;375:2423–34.
14. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J et al.
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of
atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet
2016;388:1995–2003.
15. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-vitamin K antagon-
ist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation
and heart failure: a systemic review and meta-analysis of randomized trials. Eur J
Heart Fail 2015;17:1192–200.
16. Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA et al.
Improved outcomes with European Society of Cardiology guideline-adherent
antithrombotic treatment in high-risk patients with atrial fibrillation: a report
from the EORP-AF General Pilot Registry. Europace 2015;17:1777–86.
17. Potpara TS, Dan G-A, Trendafilova E, Goda A, Kusljugic Z, Manola S et al. Stroke
prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the
Balkan Region: the BALKAN-AF Survey. Sci Rep 2016;6:20432.
18. Proietti M, Nobili A, Raparelli V, Napoleone L, Mannucci PM, Lip GYH.
Adherence to antithrombotic therapy guidelines improves mortality among eld-
erly patients with atrial fibrillation: insights from the REPOSI study. Clin Res
Cardiol 2016;105:912–20.
19. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH
et al. Asymptomatic atrial fibrillation: clinical correlates, management, and out-
comes in the EORP-AF Pilot General Registry. Am J Med 2015;128:509–18.
20. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al.
‘Real-world’ management and outcomes of patients with paroxysmal vs. non-
paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-
Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace 2016;18:648–57.
Contemporary use of OAC in European AF patients Page 11 of 11
Downloaded from https://academic.oup.com/europace/article-abstract/doi/10.1093/europace/eux301/4158403/Contemporary-stroke-prevention-strategies-in-11
by Sapienza Università di Roma user
on 14 September 2017
